Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.30 |
| ▸ | RELA | Q04206 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670340 | 0.81 | MEN1 (0.33) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL2670204 | 0.80 | MEN1 (0.35) | MEN1MAPK1KMT2AGAA | |
| SCHEMBL7517321 | 0.78 | PSEN1 (0.35) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL25201032 | 0.78 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL30325623 | 0.78 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL21335536 | 0.78 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL2301080 | 0.78 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL26607392 | 0.78 | MEN1 (0.39) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL2670185 | 0.76 | PSEN1 (0.36) | MEN1MAPK1KMT2AGAAEPHX2 | |
| SCHEMBL2670229 | 0.76 | PSEN1 (0.36) | MEN1MAPK1KMT2AGAAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | MEN1 3591/4885MAPK1 2614/4885KMT2A 2847/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | MEN1 3591/4885MAPK1 2614/4885KMT2A 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.